Endovascular Engineering (E2) has completed enrolment of subjects in the pivotal cohort of its ENGULF trial, involving the Hēlo PE Thrombectomy System. The investigational device exemption study was ...

The trial evaluates the Hēlo™ PE Thrombectomy System, a novel technology designed for the treatment of pulmonary embolism (PE)—a life-threatening condition caused by blood clots in the lungs.

AngioDynamics Announces First Patient Enrolled in RECOVER-AV Clinical Trial Evaluating AlphaVac F18 85 System for Treatment of Acute Pulmonary Embolism. Multi-center, multi-national study builds ...

Researchers determined a short duration of anticoagulation therapy could be beneficial in comparison to a longer course for primary treatment VTE.

Pulmonary embolism (PE) remains one of the leading causes of maternal mortality. At the French Thoracic Society Spring Days in May, Dr Aurélie Dehaene, radiologist at European Hospital in Marseille, ...

Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced the completion of enrollment in the STORM-PE ...

E2 (Endovascular Engineering, Inc.) Announces Completion of Enrollment in the ENGULF Pivotal Cohort for Treatment of Pulmonary Embolism Provided by PR Newswire Jun 23, 2025, 2:05:00 PM ...